Loading
NASDAQHealthcareBiotechnology
Latest quote
$10.25
−$0.17 · -1.63%
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Previous close
$10.25
−$0.17 · -1.63%
Regular session · ET · Market data may be delayed.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Day range
Current $10.25
52-week range
Current $10.25
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
34
Expensive
Sentiment
62
Bullish
Risk
57
Elevated Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Day range
Current $10.25
52-week range
Current $10.25
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 8.09M USD | 13.62M USD |
| Cost of goods sold | 1.64M USD | 2.46M USD | 2.58M USD | — | — |
| Gross profit | −1.64M USD | −2.46M USD | −2.58M USD | 8.09M USD | 13.62M USD |
| Research and development | 140.33M USD | 96.43M USD | 76.56M USD | 78.42M USD | 58.74M USD |
| Selling, general, and administrative | 38.88M USD | 33.3M USD | 27.75M USD | 28.95M USD | 27.14M USD |
| Operating expenses | 177.57M USD | 127.27M USD | 101.73M USD | 114.55M USD | 85.87M USD |
| Interest income | 9.9M USD | 9.47M USD | 7.14M USD | 2.62M USD | 64K USD |
| Interest expense | — | 340K USD | — | — | — |
| Depreciation and amortization | 1.64M USD | 2.46M USD | 2.58M USD | 2.41M USD | 2.96M USD |
| Operating income | −179.21M USD | −129.73M USD | −104.32M USD | −106.45M USD | −72.25M USD |
| Net income | −174.33M USD | −124.7M USD | −96.02M USD | −85.98M USD | −72.19M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.00
95.12% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI28.7M0.25%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI25.38M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM19.97M0.03%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF6.25M0.01%93.7B USD0.05%$242.66+0.14%
iShares Biotechnology ETFIBB5.71M0.05%10.72B USD0.44%$211.92-0.88%
Fidelity Enhanced Small Cap ETFFESM5.14M0.08%6.03B USD0.28%$47.36+0.21%
iShares Russell 2000 Value ETFIWN3.65M0.03%14.47B USD0.24%$224.62+0.40%
Vanguard Russell 2000 ETFVTWO3.56M0.02%17.4B USD0.06%$119.62+0.25%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
